Effectiveness of 14 Days Concomitant Therapy as a New Regimen in Treatment of Helicobacter Pylori Infection on a Sample of Lebanese Population

Abstract

Background: Finding new efficacious regimens for H Pylori eradication remains the goal of many studies especially after the increased resistance to standard therapy, which includes clarithromycin as the main antibiotic. In the current study, the aim is to evaluate the efficacy of concomitant or non-bismuth quadruple therapy in eradication of H Pylori. Methods: 50 patients from Al-Zahraa Hospital University Medical Center (ZHUMC) receiving concomitant therapy were included in the study from August 2015 to December 2016. Patients were presented with symptoms of gastritis, peptic ulcer diseases (epigastric pain, heartburn, halitosis, nausea…) and found to have H. pylori infection through Rapid Urease Test (RUT) following endoscopy, were included in this study. Patients were assigned into the 14 days’ concomitant non-bismuth quadruple therapy, which is consisted of Lansoprazole (30mg), amoxicillin (1g), clarithromycin (500mg) and metronidazole (500mg).Our primary endpoint was H. Pylori eradication as established by a negative urease breath test at least 2 weeks after the end of treatment. Results: All were evaluated at the end of the study. The H. pylori eradication rate was 94% (47/50). The treatment was well tolerated by the participants to the study with a 96% compliance. Conclusions: A total 14-day concomitant therapy is a highly effective treatment for H. pylori infection as showed by the high tolerance, mild and non-serious side effects in our sample of patients.